Your browser doesn't support javascript.
loading
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew, Yvette; Ledermann, Jonathan; Hall, Geoff; Rea, Daniel; Glasspool, Ros; Highley, Martin; Jayson, Gordon; Sludden, Julieann; Murray, James; Jamieson, David; Halford, Sarah; Acton, Gary; Backholer, Zoe; Mangano, Raffaella; Boddy, Alan; Curtin, Nicola; Plummer, Ruth.
Afiliación
  • Drew Y; Northern Institute for Cancer Research and the Northern Centre for Cancer Care, Newcastle Freeman Hospital Newcastle, Newcastle 0191 2139386, UK.
  • Ledermann J; UCL Cancer Institute, CR-UK and UCL Cancer Trials Centre, 90 Tottenham Court Road, London W1T 4TJ, UK.
  • Hall G; St James's University Hospital, Cancer Research UK Clinical Cancer Centre in Leeds, Beckett Street, Leeds LS9 7TF, UK.
  • Rea D; University of Birmingham, School of Cancer Sciences, Edgbaston, Birmingham B15 2TT, UK.
  • Glasspool R; Beatson West of Scotland Cancer Centre, Medical Oncology 1053 Great Western Road, Glasgow G12 0YN, UK.
  • Highley M; Derriford Hospital Plymouth Oncology Centre, Plymouth, UK.
  • Jayson G; University of Manchester, Paterson Institute for Cancer Research, Translational Angiogenesis Group, Wilmslow Road, Manchester, M20 4BX, UK.
  • Sludden J; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle, UK.
  • Murray J; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle, UK.
  • Jamieson D; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle, UK.
  • Halford S; Cancer Research UK, Drug Development Office, The Angel Building, 407 St John Street, London EC1V 4AD, UK.
  • Acton G; Cancer Research UK, Centre for Drug Development Drug Development, Angel Building, London EC1V 4AD, UK.
  • Backholer Z; Cancer Research UK, Centre for Drug Development Drug Development, Angel Building, London EC1V 4AD, UK.
  • Mangano R; Cancer Research UK, Centre for Drug Development Drug Development, Angel Building, London EC1V 4AD, UK.
  • Boddy A; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle, UK.
  • Curtin N; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle, UK.
  • Plummer R; Northern Institute for Cancer Research and the Northern Centre for Cancer Care, Newcastle Freeman Hospital Newcastle, Newcastle 0191 2139386, UK.
Br J Cancer ; 114(7): 723-30, 2016 Mar 29.
Article en En | MEDLINE | ID: mdl-27002934
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias de la Mama / Mutación de Línea Germinal / Proteína BRCA1 / Proteína BRCA2 / Indoles Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Br J Cancer Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias de la Mama / Mutación de Línea Germinal / Proteína BRCA1 / Proteína BRCA2 / Indoles Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Br J Cancer Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido